BECTON, DICKINSON AND COMPANY for BECTON DICKINSON AND COMPANY
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Trade (domestic/foreign) TRD
Understand purpose of Brazil Caucus
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANNY LY | — |
Budget/Appropriations BUD
NIH Funding FDA Funding PEPFAR
| Lobbyist | Covered position, as disclosed |
|---|---|
| JENNIFER M LURAY | — |
| DANNY LY | — |
| ELIZABETH WOODY | — |
Taxation/Internal Revenue Code TAX
H.R.523, Protect Medical Innovation Act of 2013 S.232, Medical Device Access and Innovation Protection Act Device tax amendment Corporate tax issues
| Lobbyist | Covered position, as disclosed |
|---|---|
| JENNIFER M LURAY | — |
| DANNY LY | — |
| ELIZABETH WOODY | — |
Health Issues HCR
S.959, Pharmaceutical Compounding Quality and Accountability Act, Issues related to drug compounding FDA regulation of diagnostic tests Healthcare policy and medical technology issues Issues relating to injection safety for patients and healthcare workers
| Lobbyist | Covered position, as disclosed |
|---|---|
| JENNIFER M LURAY | — |
| DANNY LY | — |
| ELIZABETH WOODY | — |
Medicare/Medicaid MMM
Diagnostic reimbursement
| Lobbyist | Covered position, as disclosed |
|---|---|
| JENNIFER M LURAY | — |
| ELIZABETH WOODY | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.